 Jun Ying
Concepts (288)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Neoplasms | 8 | 2021 | 2533 | 1.350 |
Why?
| | Folic Acid | 1 | 2023 | 186 | 0.750 |
Why?
| | Immunohistochemistry | 3 | 2019 | 1732 | 0.660 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 2 | 2019 | 1111 | 0.640 |
Why?
| | ErbB Receptors | 3 | 2019 | 610 | 0.610 |
Why?
| | Platinum Compounds | 1 | 2019 | 10 | 0.610 |
Why?
| | Fixatives | 1 | 2019 | 14 | 0.610 |
Why?
| | Genes, erbB | 1 | 2018 | 2 | 0.600 |
Why?
| | Diabetes, Gestational | 1 | 2023 | 322 | 0.600 |
Why?
| | Desiccation | 1 | 2019 | 22 | 0.600 |
Why?
| | Indicators and Reagents | 1 | 2019 | 110 | 0.590 |
Why?
| | Carcinoma, Squamous Cell | 2 | 2021 | 638 | 0.580 |
Why?
| | Circulating Tumor DNA | 1 | 2018 | 32 | 0.580 |
Why?
| | Proteoglycans | 1 | 2019 | 109 | 0.580 |
Why?
| | Neoplasm Proteins | 2 | 2019 | 433 | 0.570 |
Why?
| | Serum Albumin | 1 | 2019 | 151 | 0.570 |
Why?
| | Fibrinogen | 1 | 2019 | 173 | 0.560 |
Why?
| | Immunotherapy | 1 | 2021 | 633 | 0.500 |
Why?
| | Receptor Protein-Tyrosine Kinases | 1 | 2018 | 231 | 0.490 |
Why?
| | Mitochondria | 1 | 2023 | 958 | 0.490 |
Why?
| | Pneumonia | 2 | 2019 | 644 | 0.490 |
Why?
| | Biopsy | 1 | 2019 | 1072 | 0.460 |
Why?
| | Bone Neoplasms | 1 | 2017 | 248 | 0.440 |
Why?
| | Adenocarcinoma | 2 | 2019 | 885 | 0.440 |
Why?
| | Insulin Resistance | 1 | 2023 | 1222 | 0.430 |
Why?
| | Respiration, Artificial | 1 | 2019 | 670 | 0.420 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2018 | 801 | 0.410 |
Why?
| | Biomarkers, Tumor | 3 | 2019 | 1229 | 0.370 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2019 | 1045 | 0.340 |
Why?
| | Breast Neoplasms | 1 | 2023 | 2283 | 0.340 |
Why?
| | Lymphatic Metastasis | 2 | 2023 | 323 | 0.310 |
Why?
| | In Situ Hybridization, Fluorescence | 3 | 2019 | 310 | 0.310 |
Why?
| | Neoplasms | 2 | 2024 | 2689 | 0.280 |
Why?
| | Genes, Bacterial | 2 | 2020 | 166 | 0.280 |
Why?
| | Humans | 31 | 2024 | 139072 | 0.260 |
Why?
| | Sensitivity and Specificity | 5 | 2018 | 1942 | 0.260 |
Why?
| | Pneumonia, Viral | 2 | 2020 | 372 | 0.230 |
Why?
| | Coronavirus Infections | 2 | 2020 | 369 | 0.230 |
Why?
| | Neurofeedback | 1 | 2024 | 2 | 0.220 |
Why?
| | Female | 17 | 2024 | 74071 | 0.220 |
Why?
| | Receptors, Purinergic P2X7 | 1 | 2023 | 12 | 0.210 |
Why?
| | Mendelian Randomization Analysis | 1 | 2024 | 48 | 0.210 |
Why?
| | Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2023 | 35 | 0.210 |
Why?
| | Emergence Delirium | 1 | 2023 | 4 | 0.200 |
Why?
| | Astrocytes | 2 | 2023 | 217 | 0.200 |
Why?
| | Arrestins | 1 | 2023 | 14 | 0.200 |
Why?
| | Glycyrrhiza uralensis | 1 | 2023 | 1 | 0.200 |
Why?
| | Eucommiaceae | 1 | 2023 | 1 | 0.200 |
Why?
| | Thiamphenicol | 3 | 2020 | 3 | 0.200 |
Why?
| | Virtual Reality | 1 | 2024 | 65 | 0.200 |
Why?
| | Graphite | 1 | 2022 | 13 | 0.200 |
Why?
| | Adenomatous Polyposis Coli | 1 | 2023 | 39 | 0.200 |
Why?
| | Radiation Oncology | 1 | 2023 | 85 | 0.190 |
Why?
| | Delirium | 1 | 2024 | 97 | 0.190 |
Why?
| | Receptor, Cannabinoid, CB2 | 1 | 2022 | 11 | 0.190 |
Why?
| | Interleukin-33 | 1 | 2022 | 51 | 0.190 |
Why?
| | Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2022 | 23 | 0.190 |
Why?
| | Drug Resistance, Multiple, Bacterial | 2 | 2020 | 75 | 0.190 |
Why?
| | Neurodegenerative Diseases | 1 | 2024 | 138 | 0.180 |
Why?
| | Rectal Neoplasms | 1 | 2023 | 148 | 0.180 |
Why?
| | Aged | 6 | 2024 | 24186 | 0.180 |
Why?
| | Neuroglia | 1 | 2022 | 173 | 0.180 |
Why?
| | Mutation | 4 | 2023 | 3990 | 0.170 |
Why?
| | Chromatography, High Pressure Liquid | 3 | 2022 | 591 | 0.170 |
Why?
| | Middle Aged | 9 | 2024 | 33811 | 0.170 |
Why?
| | Colonic Neoplasms | 1 | 2023 | 247 | 0.170 |
Why?
| | Mitochondrial Proteins | 1 | 2023 | 258 | 0.170 |
Why?
| | Keloid | 1 | 2020 | 8 | 0.170 |
Why?
| | Genotype | 2 | 2023 | 1849 | 0.170 |
Why?
| | Central Nervous System | 1 | 2022 | 264 | 0.160 |
Why?
| | Convalescence | 1 | 2020 | 19 | 0.160 |
Why?
| | Proteus | 1 | 2020 | 6 | 0.160 |
Why?
| | Proteus Infections | 1 | 2020 | 5 | 0.160 |
Why?
| | Feasibility Studies | 1 | 2024 | 980 | 0.160 |
Why?
| | Osteoarthritis, Knee | 1 | 2023 | 256 | 0.160 |
Why?
| | Honey | 2 | 2010 | 11 | 0.160 |
Why?
| | Smartphone | 1 | 2020 | 89 | 0.150 |
Why?
| | Tandem Mass Spectrometry | 1 | 2022 | 556 | 0.150 |
Why?
| | Nucleic Acids | 1 | 2020 | 70 | 0.150 |
Why?
| | Dietary Supplements | 1 | 2023 | 559 | 0.150 |
Why?
| | Male | 12 | 2024 | 68299 | 0.150 |
Why?
| | Carcinoma, Adenosquamous | 1 | 2019 | 9 | 0.150 |
Why?
| | Tumor Microenvironment | 1 | 2023 | 670 | 0.150 |
Why?
| | Homeostasis | 1 | 2023 | 614 | 0.150 |
Why?
| | Ultrasonics | 1 | 2019 | 50 | 0.150 |
Why?
| | Genome, Bacterial | 1 | 2020 | 140 | 0.150 |
Why?
| | Plasmids | 1 | 2020 | 359 | 0.150 |
Why?
| | Formaldehyde | 1 | 2019 | 67 | 0.150 |
Why?
| | Liquid Biopsy | 1 | 2018 | 12 | 0.150 |
Why?
| | Synapses | 1 | 2022 | 426 | 0.140 |
Why?
| | DNA, Neoplasm | 1 | 2019 | 158 | 0.140 |
Why?
| | Scleroderma, Systemic | 1 | 2019 | 122 | 0.140 |
Why?
| | Cytodiagnosis | 1 | 2018 | 32 | 0.140 |
Why?
| | Oxygen Inhalation Therapy | 1 | 2020 | 172 | 0.140 |
Why?
| | Neoadjuvant Therapy | 1 | 2021 | 412 | 0.140 |
Why?
| | Biopsy, Fine-Needle | 1 | 2018 | 70 | 0.140 |
Why?
| | Glucose | 1 | 2023 | 1032 | 0.140 |
Why?
| | Transplantation Conditioning | 1 | 2019 | 184 | 0.140 |
Why?
| | Interferons | 1 | 2019 | 195 | 0.140 |
Why?
| | DNA Mutational Analysis | 1 | 2019 | 398 | 0.140 |
Why?
| | Transcription Factors | 2 | 2023 | 1701 | 0.140 |
Why?
| | High-Throughput Nucleotide Sequencing | 2 | 2018 | 543 | 0.140 |
Why?
| | Alzheimer Disease | 1 | 2023 | 569 | 0.140 |
Why?
| | Procollagen | 1 | 2017 | 23 | 0.130 |
Why?
| | Workflow | 1 | 2019 | 165 | 0.130 |
Why?
| | Gene Rearrangement | 1 | 2018 | 151 | 0.130 |
Why?
| | Disease-Free Survival | 1 | 2019 | 704 | 0.130 |
Why?
| | Betacoronavirus | 1 | 2020 | 273 | 0.130 |
Why?
| | ROC Curve | 1 | 2019 | 564 | 0.130 |
Why?
| | Peptides | 1 | 2023 | 980 | 0.130 |
Why?
| | Cisplatin | 1 | 2019 | 327 | 0.130 |
Why?
| | Bone Remodeling | 1 | 2017 | 77 | 0.130 |
Why?
| | Alkaline Phosphatase | 1 | 2017 | 149 | 0.130 |
Why?
| | Collagen Type I | 1 | 2017 | 139 | 0.130 |
Why?
| | Feces | 1 | 2020 | 486 | 0.130 |
Why?
| | Kaplan-Meier Estimate | 1 | 2019 | 897 | 0.130 |
Why?
| | Receptor, ErbB-2 | 1 | 2019 | 349 | 0.130 |
Why?
| | beta-Lactamases | 1 | 2016 | 49 | 0.130 |
Why?
| | Imaging, Three-Dimensional | 1 | 2020 | 564 | 0.120 |
Why?
| | Gastrointestinal Microbiome | 1 | 2024 | 699 | 0.120 |
Why?
| | Phycocyanin | 1 | 2015 | 4 | 0.120 |
Why?
| | Spirulina | 1 | 2015 | 4 | 0.120 |
Why?
| | Temperature | 1 | 2019 | 660 | 0.120 |
Why?
| | Myostatin | 1 | 2015 | 25 | 0.120 |
Why?
| | Proportional Hazards Models | 1 | 2019 | 1281 | 0.120 |
Why?
| | Macrophages | 1 | 2023 | 1544 | 0.120 |
Why?
| | Colorectal Neoplasms | 1 | 2023 | 792 | 0.120 |
Why?
| | Gene Knockout Techniques | 1 | 2015 | 116 | 0.110 |
Why?
| | Homocysteine S-Methyltransferase | 1 | 2015 | 5 | 0.110 |
Why?
| | Gene Transfer, Horizontal | 1 | 2015 | 35 | 0.110 |
Why?
| | Escherichia coli Proteins | 1 | 2016 | 200 | 0.110 |
Why?
| | Prospective Studies | 4 | 2023 | 7666 | 0.110 |
Why?
| | Cognition | 1 | 2022 | 1179 | 0.110 |
Why?
| | CRISPR-Cas Systems | 1 | 2015 | 134 | 0.110 |
Why?
| | Dogs | 1 | 2015 | 426 | 0.110 |
Why?
| | Phylogeny | 2 | 2016 | 1000 | 0.110 |
Why?
| | Vitamin D | 1 | 2017 | 399 | 0.100 |
Why?
| | Calixarenes | 1 | 2013 | 5 | 0.100 |
Why?
| | Chorionic Gonadotropin, beta Subunit, Human | 1 | 2013 | 16 | 0.100 |
Why?
| | Angiopoietin-2 | 1 | 2013 | 15 | 0.100 |
Why?
| | Neutrophils | 1 | 2019 | 1274 | 0.100 |
Why?
| | Peptide Fragments | 1 | 2017 | 694 | 0.100 |
Why?
| | Internship and Residency | 1 | 2023 | 1185 | 0.100 |
Why?
| | Uterine Hemorrhage | 1 | 2013 | 38 | 0.100 |
Why?
| | Transcriptome | 1 | 2019 | 969 | 0.100 |
Why?
| | Databases, Factual | 1 | 2019 | 1412 | 0.100 |
Why?
| | Protein Kinase Inhibitors | 1 | 2018 | 907 | 0.100 |
Why?
| | Treatment Outcome | 4 | 2020 | 10930 | 0.100 |
Why?
| | Aging | 1 | 2023 | 1857 | 0.090 |
Why?
| | Phenols | 1 | 2013 | 104 | 0.090 |
Why?
| | Escherichia coli | 1 | 2016 | 827 | 0.090 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2018 | 1058 | 0.090 |
Why?
| | Pregnancy | 2 | 2023 | 6872 | 0.090 |
Why?
| | Organometallic Compounds | 1 | 2013 | 112 | 0.090 |
Why?
| | Abortion, Induced | 1 | 2013 | 102 | 0.090 |
Why?
| | Time Factors | 3 | 2019 | 6869 | 0.090 |
Why?
| | Disease Progression | 1 | 2019 | 2752 | 0.090 |
Why?
| | Chemical Fractionation | 1 | 2010 | 30 | 0.080 |
Why?
| | Food Analysis | 1 | 2010 | 26 | 0.080 |
Why?
| | Heart Atria | 1 | 2010 | 137 | 0.080 |
Why?
| | Genetic Variation | 1 | 2015 | 990 | 0.080 |
Why?
| | Risk Factors | 2 | 2024 | 10390 | 0.070 |
Why?
| | Chloramphenicol | 1 | 2008 | 10 | 0.070 |
Why?
| | Exercise Tolerance | 1 | 2010 | 278 | 0.070 |
Why?
| | Bacteria | 1 | 2015 | 868 | 0.070 |
Why?
| | Radiology, Interventional | 1 | 2008 | 32 | 0.070 |
Why?
| | Adult | 6 | 2024 | 38428 | 0.070 |
Why?
| | China | 2 | 2020 | 214 | 0.070 |
Why?
| | Lung | 1 | 2021 | 4107 | 0.070 |
Why?
| | Radiation Protection | 1 | 2008 | 38 | 0.070 |
Why?
| | Biomarkers | 1 | 2019 | 4095 | 0.070 |
Why?
| | Antineoplastic Agents | 1 | 2019 | 2153 | 0.070 |
Why?
| | Prognosis | 3 | 2023 | 3999 | 0.070 |
Why?
| | Education, Medical, Continuing | 1 | 2008 | 132 | 0.060 |
Why?
| | Aged, 80 and over | 1 | 2018 | 7686 | 0.060 |
Why?
| | Radiation Dosage | 1 | 2008 | 188 | 0.060 |
Why?
| | Apoptosis | 1 | 2015 | 2552 | 0.060 |
Why?
| | Animals | 6 | 2023 | 37261 | 0.060 |
Why?
| | Heart Transplantation | 1 | 2010 | 708 | 0.050 |
Why?
| | Sphingomyelins | 1 | 2024 | 22 | 0.050 |
Why?
| | Purinergic P2X Receptor Antagonists | 1 | 2023 | 7 | 0.050 |
Why?
| | beta-Arrestins | 1 | 2023 | 14 | 0.050 |
Why?
| | Dynamins | 1 | 2023 | 38 | 0.050 |
Why?
| | Matrix Metalloproteinase 13 | 1 | 2023 | 24 | 0.050 |
Why?
| | Aggrecans | 1 | 2023 | 15 | 0.050 |
Why?
| | Shellfish | 1 | 2022 | 6 | 0.050 |
Why?
| | Solid Phase Extraction | 1 | 2022 | 25 | 0.050 |
Why?
| | Mitochondrial Dynamics | 1 | 2023 | 40 | 0.050 |
Why?
| | Tetrodotoxin | 1 | 2022 | 40 | 0.050 |
Why?
| | Molecular Docking Simulation | 1 | 2023 | 111 | 0.050 |
Why?
| | Porosity | 1 | 2022 | 99 | 0.050 |
Why?
| | Faculty | 1 | 2023 | 150 | 0.050 |
Why?
| | Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha | 1 | 2022 | 41 | 0.050 |
Why?
| | Hydrophobic and Hydrophilic Interactions | 1 | 2022 | 188 | 0.050 |
Why?
| | PPAR gamma | 1 | 2023 | 180 | 0.050 |
Why?
| | Cholesterol, LDL | 1 | 2024 | 359 | 0.050 |
Why?
| | Microglia | 1 | 2024 | 256 | 0.040 |
Why?
| | Pandemics | 2 | 2020 | 1645 | 0.040 |
Why?
| | Carbon | 1 | 2022 | 203 | 0.040 |
Why?
| | Mice | 3 | 2023 | 17836 | 0.040 |
Why?
| | Educational Status | 1 | 2023 | 475 | 0.040 |
Why?
| | Brain | 2 | 2024 | 2794 | 0.040 |
Why?
| | Inflammation | 2 | 2022 | 2853 | 0.040 |
Why?
| | Neurogenesis | 1 | 2022 | 153 | 0.040 |
Why?
| | Chromatography, Liquid | 1 | 2022 | 449 | 0.040 |
Why?
| | Mammals | 1 | 2022 | 286 | 0.040 |
Why?
| | Pain Management | 1 | 2024 | 389 | 0.040 |
Why?
| | Molecular Targeted Therapy | 1 | 2023 | 413 | 0.040 |
Why?
| | Molecular Sequence Data | 2 | 2015 | 2926 | 0.040 |
Why?
| | Thorax | 1 | 2020 | 50 | 0.040 |
Why?
| | Pediatrics | 1 | 2008 | 1079 | 0.040 |
Why?
| | Pathologists | 1 | 2019 | 18 | 0.040 |
Why?
| | Molecular Structure | 2 | 2013 | 502 | 0.040 |
Why?
| | Myeloablative Agonists | 1 | 2019 | 23 | 0.040 |
Why?
| | Multilevel Analysis | 1 | 2019 | 35 | 0.040 |
Why?
| | Autophagy | 1 | 2022 | 286 | 0.040 |
Why?
| | Osmolar Concentration | 2 | 2010 | 167 | 0.040 |
Why?
| | Whole Genome Sequencing | 1 | 2020 | 163 | 0.040 |
Why?
| | Cyclophosphamide | 1 | 2019 | 255 | 0.040 |
Why?
| | Cloning, Molecular | 1 | 2020 | 534 | 0.040 |
Why?
| | Observer Variation | 1 | 2019 | 350 | 0.040 |
Why?
| | Microbial Sensitivity Tests | 1 | 2020 | 351 | 0.040 |
Why?
| | Lipid Metabolism | 1 | 2022 | 523 | 0.040 |
Why?
| | Transplantation, Autologous | 1 | 2019 | 276 | 0.040 |
Why?
| | Hydrogen-Ion Concentration | 2 | 2010 | 557 | 0.040 |
Why?
| | Reproducibility of Results | 2 | 2020 | 3315 | 0.030 |
Why?
| | Genome-Wide Association Study | 1 | 2024 | 1391 | 0.030 |
Why?
| | R Factors | 1 | 2016 | 1 | 0.030 |
Why?
| | Down-Regulation | 1 | 2019 | 636 | 0.030 |
Why?
| | Oxidative Stress | 1 | 2023 | 1318 | 0.030 |
Why?
| | Anxiety | 1 | 2024 | 1071 | 0.030 |
Why?
| | Retrospective Studies | 3 | 2019 | 15919 | 0.030 |
Why?
| | Hospitals, Teaching | 1 | 2016 | 115 | 0.030 |
Why?
| | Up-Regulation | 1 | 2019 | 853 | 0.030 |
Why?
| | Mice, Knockout | 1 | 2023 | 3029 | 0.030 |
Why?
| | Escherichia coli Infections | 1 | 2016 | 115 | 0.030 |
Why?
| | Burns | 1 | 2020 | 341 | 0.030 |
Why?
| | Electrophoresis, Gel, Two-Dimensional | 1 | 2015 | 112 | 0.030 |
Why?
| | Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2015 | 144 | 0.030 |
Why?
| | Hypertrophy | 1 | 2015 | 136 | 0.030 |
Why?
| | Muscular Diseases | 1 | 2015 | 112 | 0.030 |
Why?
| | Neoplasm Staging | 1 | 2019 | 1374 | 0.030 |
Why?
| | Genomics | 1 | 2020 | 797 | 0.030 |
Why?
| | Critical Care | 1 | 2020 | 654 | 0.030 |
Why?
| | Caspases | 1 | 2015 | 246 | 0.030 |
Why?
| | Exons | 1 | 2015 | 354 | 0.030 |
Why?
| | Survival Rate | 1 | 2019 | 1936 | 0.030 |
Why?
| | Cross Infection | 1 | 2016 | 249 | 0.030 |
Why?
| | DNA Primers | 1 | 2015 | 509 | 0.030 |
Why?
| | Patient Discharge | 1 | 2020 | 915 | 0.030 |
Why?
| | Chromosome Mapping | 1 | 2015 | 505 | 0.030 |
Why?
| | Species Specificity | 1 | 2015 | 581 | 0.030 |
Why?
| | Neurons | 1 | 2022 | 1602 | 0.030 |
Why?
| | Anions | 1 | 2013 | 32 | 0.030 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2019 | 662 | 0.030 |
Why?
| | Misoprostol | 1 | 2013 | 16 | 0.030 |
Why?
| | Mifepristone | 1 | 2013 | 63 | 0.030 |
Why?
| | Cluster Analysis | 1 | 2015 | 517 | 0.030 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2019 | 1523 | 0.020 |
Why?
| | Silver | 1 | 2013 | 38 | 0.020 |
Why?
| | Pregnancy Trimester, First | 1 | 2013 | 137 | 0.020 |
Why?
| | Reactive Oxygen Species | 1 | 2015 | 627 | 0.020 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2015 | 554 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2020 | 2853 | 0.020 |
Why?
| | Amino Acid Sequence | 1 | 2015 | 2160 | 0.020 |
Why?
| | Base Sequence | 1 | 2015 | 2176 | 0.020 |
Why?
| | Ethane | 1 | 2010 | 2 | 0.020 |
Why?
| | Hydrocarbons, Chlorinated | 1 | 2010 | 23 | 0.020 |
Why?
| | Pulmonary Ventilation | 1 | 2010 | 84 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 1 | 2020 | 2697 | 0.020 |
Why?
| | Sodium Chloride | 1 | 2010 | 138 | 0.020 |
Why?
| | Anti-Bacterial Agents | 1 | 2020 | 1819 | 0.020 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2015 | 1395 | 0.020 |
Why?
| | Ovarian Neoplasms | 1 | 2015 | 573 | 0.020 |
Why?
| | Eye Protective Devices | 1 | 2008 | 8 | 0.020 |
Why?
| | Solvents | 1 | 2008 | 112 | 0.020 |
Why?
| | Radiation, Ionizing | 1 | 2008 | 80 | 0.020 |
Why?
| | Models, Molecular | 1 | 2013 | 1599 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2015 | 2482 | 0.020 |
Why?
| | Cell Line, Tumor | 1 | 2015 | 3399 | 0.020 |
Why?
| | Echocardiography | 1 | 2010 | 638 | 0.020 |
Why?
| | RNA, Messenger | 1 | 2015 | 2818 | 0.020 |
Why?
| | Exercise Test | 1 | 2010 | 621 | 0.020 |
Why?
| | Fluoroscopy | 1 | 2008 | 166 | 0.020 |
Why?
| | Radiation Injuries | 1 | 2008 | 147 | 0.020 |
Why?
| | Safety | 1 | 2008 | 348 | 0.020 |
Why?
| | Occupational Exposure | 1 | 2008 | 340 | 0.010 |
Why?
| | Young Adult | 1 | 2013 | 13378 | 0.010 |
Why?
|
|
Ying's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|